Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: A multicenter prospective study

Do Young Kim, Beom Jin Park, Yun Hwan Kim, Kwang Hyub Han, Sung Bum Cho, Kyu Ran Cho, Sun Ho Uhm, Jae Gol Choe, Jong Young Choi, Ho Jong Chun, Han Chu Lee, Dong Il Gwon, Kwang Hun Lee, Jung Hwan Yoon, Jin Wook Chung, Chang Won Kim, Jeong Heo, Jae Kyu Kim, Young Eun Joo

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Objectives: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (90Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). Methods: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. Results: Forty-two treatments of 90Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0%), 19 (47.5%), and 15 (37.5%) patients, respectively. The response rate was 57.5% (23/40), and disease control rate was 95% (38/40) at 3 months. The response rate at 6 months was 63.9% (23/36), and disease control rate was 83.3% (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75%. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50%. The tumor number (> 5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65%) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion. Conclusions: 90Y radioembolization might be a safe and effective treatment modality in intermediate-stage to advanced-stage HCC.

Original languageEnglish
Pages (from-to)495-501
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
Publication statusPublished - 2015 Oct 1

Bibliographical note

Publisher Copyright:
Copyright © 2013 Wolters Kluwer Health, Inc.


  • Hepatocellular carcinoma
  • Radioembolization
  • Yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: A multicenter prospective study'. Together they form a unique fingerprint.

Cite this